Effect of a Single Colecalciferol Dose on Insulin Resistance
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01075022 |
Recruitment Status : Unknown
Verified February 2010 by Hospital de Clinicas de Porto Alegre.
Recruitment status was: Enrolling by invitation
First Posted : February 24, 2010
Last Update Posted : February 24, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Insulin Resistance Glucose Intolerance | Drug: Colecalciferol (Vitamin D3) 300.000 UI Drug: Placebo | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 136 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Effect of a Single Colecalciferol Dose on Insulin Resistance: A Prospective Randomized Trial |
Study Start Date : | May 2009 |
Estimated Primary Completion Date : | July 2010 |
Estimated Study Completion Date : | July 2010 |
Arm | Intervention/treatment |
---|---|
Experimental: Vitamin D |
Drug: Colecalciferol (Vitamin D3) 300.000 UI
Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose |
Placebo Comparator: Placebo |
Drug: Placebo
Placebo Capsule, Single Dose |
- Blood Glucose Level [ Time Frame: Baseline and day 90 ]
- Blood Calcium Level [ Time Frame: Baseline and day 90 ]
- HOMA-R [ Time Frame: Baseline and day 90 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Fasten Blood Glucose > 100 mg/dL and < 126 mg/dL
- Age > 18 years
Exclusion Criteria:
- Diabetes Mellitus
- Use of metformin
- Vitamin D Use
- Hypercalcemia
- Chronic Hepatitis
- HIV

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01075022
Brazil | |
Hospital de Clínicas de Porto Alegre | |
Porto Alegre, Rio Grande do Sul, Brazil, 90035-903 |
Study Director: | Tania Furlanetto, PhD | Federal University of Rio Grande do Sul |
Responsible Party: | Gustavo Faulhaber, Hospital de Clínicas de Porto Alegre |
ClinicalTrials.gov Identifier: | NCT01075022 History of Changes |
Other Study ID Numbers: |
33598290 |
First Posted: | February 24, 2010 Key Record Dates |
Last Update Posted: | February 24, 2010 |
Last Verified: | February 2010 |
Additional relevant MeSH terms:
Hyperinsulinism Insulin Resistance Glucose Intolerance Glucose Metabolism Disorders Metabolic Diseases Hyperglycemia Vitamins |
Vitamin D Ergocalciferols Cholecalciferol Micronutrients Growth Substances Physiological Effects of Drugs Bone Density Conservation Agents |